Bull&Bear | Fitell and IGM Biosciences Lead Gains as iTeos Therapeutics Plummets

In the realm of bullish stocks, Fitell (FTEL) experienced a significant surge of 30.67%. Over the past week, Fitell Corporation saw a market capitalization increase of $55 million, benefiting its internal stakeholders the most.

IGM Biosciences (IGMS) rose by 28.78%, marking a two-day consecutive increase of 39.07%. The company is poised to present at the 2024 Stifel Virtual Immunology and Inflammation Summit.

Nuvalent (NUVL) saw an increase of 28.27%, following a two-day upward trend with a total gain of 37.33%. The company highlighted that two potential lung cancer drugs have shown "good tolerance."

Complete Solaria (CSLR) climbed by 18.18%, continuing a six-day rally resulting in a 44.44% increase. The company raised $40.5 million to acquire assets from Zhongsheng Group.

Gevo (GEVO) increased by 17.95% over four days, achieving a 98.56% rise. The stock's upward movement was driven by the announcement of a U.S. patent for converting ethanol to olefins (ETO), cementing its position in the renewable biofuel and chemical production sector.

On the bearish side, iTeos Therapeutics (ITOS) fell 27.54% over two days, with a total decline of 28.40%. This marks its largest percentage drop since May 2022.

Instil Bio (TIL) saw its shares decrease by 23.91% following the announcement of a 60% workforce reduction aimed at prioritizing its cancer treatment projects.

Coherus Biosciences (CHRS) experienced a decline of 19.23% due to temporary supply chain disruptions. The company is focused on managing UDENYCA supply interruptions and reducing costs.

Sterling Bancorp (SBT) dropped 18.96%, as alerted by shareholders. An investigation is underway by Ademi LLP regarding whether Sterling Bancorp, Inc. secured a fair price for its public shareholders.

Sutro Biopharma (STRO) saw its stock fall by 17.78%. The company provided updates at the 2024 poster presentation on the ongoing Phase 1 study of Luvidumab Tesonibulin combined with Bevacizumab for the treatment of epithelial ovarian cancer.